The influence of antipsychotic therapy on the cognitive functions of schizophrenic patients;Wpływ leków przeciwpsychotycznych na funkcje poznawcze u pacjentów ze schizofrenią

Psychiatria Polska

Volumn 47, Issue 4, 2013, Pages 567-578

  Tybura, Piotr ^a   Mak, Monika ^a   Samochowiec, Agnieszka ^a,b   Pełka Wysiecka, Justyna ^a   Grzywacz, Anna ^a   Grochans, Elzbieta ^a   Zaremba Pechmann, Liliana ^a   Samochowiec, Jerzy ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Uniwersytetu Szczeci skiego   (Poland)

Author keywords

Cognitive functions; Neuroleptics; Schizophrenia

Indexed keywords

OLANZAPINE; PERAZINE; ZIPRASIDONE;

ADULT; ARTICLE; CAUCASIAN; COGNITION; COMPOSITE INTERNATIONAL DIAGNOSTIC INTERVIEW; CONTROLLED STUDY; DRUG EFFICACY; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; WISCONSIN CARD SORTING TEST; WORKING MEMORY;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PERAZINE; PIPERAZINES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; THIAZOLES; TREATMENT OUTCOME;

EID: 84880900796     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: 10.12740/pp/17946     Document Type: Article

References (55)

1. Stahl SM. Antipsychotics and mood stabilizers, third edition. New York: Cambridge University Press; 2008.
2. Andreasen NC. Symptoms, signs and diagnosis of schizophrenia. Lancet 1995; 346: 477-81.
3. Crow TJ. Positive and negative symptoms of schizophrenia and the role of dopamine. Br. J. Psychiatry 1980; 137: 383-386.
4. Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch. Gen. Psychiatry 2007; 64: 532-542.
5. Green MF, Nuechterlein KH, Kern RS i in. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS psychometric and standardization study. Am. J. Psychiatry 2008; 165: 221-228.
6. Barch DM. Cognition in schizophrenia: Does working memory work? Curr. Dir. Psychol. Sci. 2003; 12 (4): 146-150.
7. Green MF, Kern RS, Braff DL i in. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? Schizophr. Bull. 2000; 26 (1): 119-136.
8. Barch DM, Csernansky J, Conturo T i in. Working and long-term memory deficits in schizophrenia. Is there a common underlying prefrontal mechanism? J. Abnorm. Psychol. 2002; 111: 478-494.
9. Hoff AL, Kremen WS. Neuropsychology in schizophrenia: an update. Curr. Opin. Psychiatry 2003; 16: 149-156.
10. Wobrock T, Ecker UK, Scherk H i in. Cognitive impairment of executive function as a core symptom of schizophrenia. World J. Biol. Psychiatry 2009; 10: 442-451.
11. Goldman-Rakic P. Prefrontal cortical dysfunction in schizophrenia. The relevance of working memory. Psychopatol. Brain. New York: Raven Press; 1991.
12. Bowie CR, Harvey PD. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr. Dis. Treat. 2006; 2 (4): 531-536.
13. Serretti A, De RD, Lorenzi C i in. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr. Med. Chem. 2004; 1: 343-358.
14. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus firstgeneration antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
15. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 2009; 23: 649-659.
16. Lewis S, Lieberman J. CATIE and CUtLASS: can we handle the truth? Br. J. Psychiatry 2008; 192: 161-163.
17. Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK. CATIE Investigators. Results of phase 3 of the CATIE schizophrenia trial. Schizophr. Res. 2009; 107: 1-12.
18. Lieberman JA. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch. Gen. Psychiatry 2006; 63: 1069-1072.
19. Robins LE, Wing J, Wittchen HU, Helzer JE i in. The Composite International Diagnostic Interview: an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch. Gen. Psychiatry 1988; 45: 1069-1077.
20. Everitt BS, Vessely S. Clinical trials in psychiatry, second edition. Chichester: Wiley; 2008.
21. Jarema M, Kiejna A, Landowski J, Meder J, Rabe-Jabłonska J, Rybakowski J. Standardy leczenia farmakologicznego schizofrenii. Psychiatr. Pol. 2006; 40: 1171-1205.
22. Kay SR, Fiszbein A, Opler L. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr. Bull. 1987; 13: 261-276.
23. Haut MW, Cahill J, Cutlip WD i in. On the nature of Wisconsin Card Sorting Test performance in schizophrenia. Psychiatry Res. 1996; 65 (1): 15-22.
24. Heaton R. Wisconsin Card Sorting Test Manual revised and expanded. Odessa, Fl: Psychological Assessment Resources; 1993.
25. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr. Res. 2007; 89: 211-224.
26. McGurk SR, Lee MA, Jayathilake K, Meltzer HY. Cognitive effects of olanzapine treatment in schizophrenia. Med. Gen. Med. 2004: 10 (6): 27.
27. Harvey PD, Meltzer H, Simpson GM i in. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine or risperidone in outpatients with schizophrenia. Schizophr. Res. 2004; 66: 101-113.
28. Leucht S, Hartung B. Perazine for schizophrenia. Cochrane Database Syst. Rev. 2006; 2: CD002832.
29. Nemeroff CB, Lieberman JA, Weiden PJ i in. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr. 2005; 11 (17): 1-20.
30. Geddes J, Freemantle N, Harrison P i in. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-1376.
31. Woodward ND, Purdon SE, Meltzer HY i in. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005; 8: 457-472.
32. Rybakowski J, Borkowska A. The effect of treatment with risperidone, olanzapine or phenothiazines on cognitive functions in patients with schizophrenia. Int. J. Psychiatry Clin. Pract.2001; 5: 249-256.
33. Tybura P, Samochowiec A, Beszlej A i in. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacol. Rep. 2012; 64 (3): 528-535.
34. Tybura P, Grzywacz A, Samochowiec A, Samochowiec J. Analiza genów kandydujacych zwiazanych z predyspozycja do schizofrenii i z efektem leczenia przeciwpsychotycznego. Psychiatr. Pol. 2011; 6: 811-823.
35. Tybura P, Trzesniowska-Drukała B, Samochowiec J. Pharmacogenetics of antipsychotic drugs in schizophrenia treatment. Curr. Psychopharmacol. 2012; 1: 47-60.
36. Mortimer AM. Cognitive function in schizophrenia-do neuroleptics make a difference? Pharmacol. Biochem. Behav. 1997; 4: 789-795.
37. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: Effects on neuropsychological function in chronic schizophrenic patients. Schizophr. Bull. 1990; 3: 477-499.
38. Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am. J. Psychiatry 2004; 161: 116-124.
39. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry 1994; 55: 82-87.
40. Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophr. Bull. 1999; 25: 201-222.
41. Green MF. Recent studies on the neurocognitive effects of second-generation antipsychotic medications. Curr. Opin. Psychiatry 2002; 15 (1): 25-29.
42. Bilder RM, Goldman, RS, Volavka J i in. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry 2002; 159: 1018-1028.
43. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: A longitudinal study. Schizophr. Bull. 2001; 48: 17-28.
44. Mori K, Nagao M, Yamashita H, Morinobu S, Yamawaki S. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004; 28: 659-665.
45. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J. Psychiatr. Neurosci. 2001; 26: 137-149.
46. Velligan DI, Newcomer J, Pultz J i in. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr. Res. 2002; 53: 239-248.
47. Selva-Vera G, Balanzá-Martínez V, Salazar-Fraile J i in. The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia. BMC Psychiatry 2010; 15 (10): 47.
48. Bender S, Dittmann-Balcar A, Schall U i in. Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: A randomized, double-blind comparison of olanzapine vs. clozapine. Int. J. Neuropsychopharmacol. 2006; 9: 2: 135-145.
49. Rollnik JD, Borsutzky M, Huber TJ i in. Short-term cognitive improvement in Schizophrenics treated with typical and atypical neuroleptics. Neuropsychobiol. 2002; 45; 2: 74-80.
50. Kucharska-Pietura K, Tylec A, Czernikiewicz A, Mortimer A. Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs. Med. Sci. Monit. 2012; 18; 1: 44-49.
51. Mak M, Samochowiec J, Tybura P, Bienkowski P, Karakiewicz B, Zaremba-Pechmann L, Mroczek B. The efficacy of cognitive rehabilitation with RehaCom programme in schizophrenia patients. The role of selected genetic polymorphisms in successful cognitive rehabilitation. Ann. Agric. Environ. Med. 2013; 20 (1): 77-81.
52. Mak M, Tybura P, Bienkowski P, Karakiewicz B, Samochowiec J. Skutecznosć rehabilitacji neuropsychologicznej z wykorzystaniem programów RehaCom u pacjentów z rozpoznana schizofrenia. Psychiatr. Pol. 2013; 2: 213-223.
53. Samochowiec A, Horodnicki JM, Samochowiec J. Wpływ cech osobowosci i polimorfizmów genów DRD4 i 5HTT rodziców na predyspozycje ich synów do uzaleznienia sie od alkoholu. Psychiatr. Pol. 2011; 45 (3): 337-347.
54. Suchanecka A, Grzywacz A, Samochowiec J. Gen ANKK1 w psychiatrii. Psychiatr. Pol. 2011; 45 (3): 349-356.
55. Tybura P, Grzywacz A, Konopka A, Samochowiec J. Association of functional genes polymorphisms of key enzymes in the metabolism of biogenic amines with paranoid schizophrenia susceptibility and the influence of these polymorphisms on PANSS results in antipsychotic treatment. Arch. Psychiatry Psychother. 2007; 9 (3): 5-11 .